Sugi Predict

Sugi Predict / Targets / SUMO3

SUMO3

Small ubiquitin-related modifier 3 (SUMO-3) ( · P55854 · SUMO3 on Sugi Atlas →

236 patent compounds predicted against SUMO3, 150 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1091100 SCHEMBL1091100 0.54 2/20
SCHEMBL7418050 SCHEMBL7418050 0.43 2/20
SCHEMBL9287754 SCHEMBL9287754 0.72 1/20
SCHEMBL7688411 SCHEMBL7688411 0.68 1/20
SCHEMBL4089465 SCHEMBL4089465 0.61 1/20
SCHEMBL1062608 SCHEMBL1062608 0.60 1/20
SCHEMBL12408745 SCHEMBL12408745 0.58 1/20
SCHEMBL4977971 SCHEMBL4977971 0.58 1/20
SCHEMBL4980653 SCHEMBL4980653 0.58 1/20
SCHEMBL4864986 SCHEMBL4864986 0.56 1/20
SCHEMBL1091107 SCHEMBL1091107 0.55 1/20
SCHEMBL1089924 SCHEMBL1089924 0.54 1/20
SCHEMBL1091029 SCHEMBL1091029 0.54 1/20
SCHEMBL1091049 SCHEMBL1091049 0.54 1/20
SCHEMBL5411231 SCHEMBL5411231 0.54 1/20
SCHEMBL11237247 SCHEMBL11237247 0.53 1/20
SCHEMBL5238637 SCHEMBL5238637 0.53 1/20
SCHEMBL3638028 SCHEMBL3638028 0.53 1/20
SCHEMBL4864291 SCHEMBL4864291 0.52 1/20
SCHEMBL16000121 SCHEMBL16000121 0.51 1/20

Clinical trials — most relevant to SUMO3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) PHASE3COMPLETED
REbif FLEXible Dosing in Early Multiple Sclerosis (MS) PHASE3COMPLETED
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Oral Nitrite for Older Heart Failure Patients PHASE2COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases nanUNKNOWN
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas nanRECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome nanCOMPLETED
Molecular Biomarkers Associated With Degenerative Joint Disease in the Knee nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Expression and Clinical Significance of IGHD in Pancreatic Cancer nanUNKNOWN
Genetic Analysis to Predict the Development of Paget's Disease nanACTIVE_NOT_RECRUITING
Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis nanCOMPLETED
Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study nanCOMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS nanRECRUITING
Genetic Studies of Inflammatory Bowel Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SUMO3 binder may also engage these)

ProteinNameSimilarity
Q5XIF4 — 1.000 Q5XIF4 →
Q6DI05 — 1.000 Q6DI05 →
Q2PFW2 — 1.000 Q2PFW2 →
P61959 — 1.000 P61959 →
Q9Z172 — 1.000 Q9Z172 →
Q6LDZ8 — 1.000 Q6LDZ8 →
P61957 — 1.000 P61957 →
Q17QV3 — 1.000 Q17QV3 →
Q6DHL4 — 1.000 Q6DHL4 →
Q6GPW2 — 1.000 Q6GPW2 →
Q6NV25 — 1.000 Q6NV25 →
Q5ZHQ1 — 0.999 Q5ZHQ1 →
Q28H04 — 0.998 Q28H04 →
Q7ZTK7 — 0.998 Q7ZTK7 →
A7WLI0 — 0.998 A7WLI0 →
Q5ZJM9 — 0.997 Q5ZJM9 →
P61955 — 0.997 P61955 →
SUMO2 Small ubiquitin-related modifier 2 0.997 landscape →
P61958 — 0.997 P61958 →
Q6DK72 — 0.996 Q6DK72 →
Q7SZ22 — 0.996 Q7SZ22 →
P55852 — 0.996 P55852 →
Q12306 — 0.995 Q12306 →
Q6EEV6 — 0.994 Q6EEV6 →
G2XKQ0 — 0.992 G2XKQ0 →
Q9FLP6 — 0.991 Q9FLP6 →
O13351 — 0.989 O13351 →
Q3E8A8 — 0.989 Q3E8A8 →
B3H5R8 — 0.987 B3H5R8 →
P55857 — 0.983 P55857 →